Table 3 Cost effectiveness analysis results
Treatment options | Total cost ($) | Total effectiveness (QALY) | Incremental cost ($) | Incremental effectiveness (QALY) | ICER ($/QALY) | Decision |
|---|---|---|---|---|---|---|
SoC | 21.292,16 | 2.94 | – | – | – | Dominant |
Aducanumab | 98.068,49 | 3.58 | 76.776,33 | 0.64 | 119.482,80 | Â |